Jane Street’s Accelerate Diagnostics AXDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-22,415
Closed -$26.9K 9406
2024
Q4
$26.9K Buy
+22,415
New +$37.2K ﹤0.01% 9093
2022
Q4
Sell
-4,862
Closed -$73K 9116
2022
Q3
$73K Sell
4,862
-5,202
-52% -$86.1K ﹤0.01% 8777
2022
Q2
$100K Buy
+10,064
New +$88.9K ﹤0.01% 8635
2021
Q4
Sell
-1,365
Closed -$80K 10029
2021
Q3
$80K Buy
+1,365
New +$89K ﹤0.01% 9383
2021
Q1
Sell
-2,569
Closed -$261K 9072
2020
Q4
$195K Buy
+2,569
New +$230K ﹤0.01% 6962
2020
Q3
Sell
-1,128
Closed -$171K 7132
2020
Q2
$171K Buy
+1,128
New +$111K ﹤0.01% 6464
2019
Q2
Sell
-3,086
Closed -$648K 5114
2019
Q1
$648K Buy
3,086
+336
+12% +$63K ﹤0.01% 3357
2018
Q4
$316K Buy
+2,750
New +$407K ﹤0.01% 4006
2018
Q1
Sell
-13,364
Closed -$3.5M 4782
2017
Q4
$3.5M Buy
13,364
+4,219
+46% +$989K 0.01% 1103
2017
Q3
$2.05M Buy
+9,145
New +$2.25M 0.01% 1571
2014
Q3
Sell
-12,004
Closed -$3.12M 2524
2014
Q2
$3.12M Buy
12,004
+10,329
+617% +$2.25M 0.04% 376
2014
Q1
$365K Buy
+1,675
New +$248K ﹤0.01% 1824
2013
Q3
Sell
-1,105
Closed -$90K 2695
2013
Q2
$90K Buy
+1,105
New +$82K ﹤0.01% 2454

Other funds holding AXDX

Jane Street's AXDX Position: Q1 2025 in Review

Jane Street sold out of Accelerate Diagnostics (AXDX) in Q1 2025, closing a stake of 22,415 shares — an estimated $26.9K sold.

Jane Street first reported a position in AXDX in Q2 2013 and held it in 13 quarters. The position peaked at $3.5M in Q4 2017. 43 funds tracked by Wall St. Rank hold AXDX as of Q1 2025.

  • Jane Street reported no remaining Accelerate Diagnostics position as of Q1 2025 after selling out during the quarter.
  • Jane Street sold 22,415 Accelerate Diagnostics shares in Q1 2025, an estimated $26.9K.
  • Jane Street first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 13 quarters.
  • Jane Street's Accelerate Diagnostics position peaked at $3.5M in Q4 2017.
  • 43 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2025.

Based on Jane Street's 13F filing for Q1 2025, filed 14 May 2025.